Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

HCW Biologics (HCWB) Equity Average (2020 - 2025)

Historic Equity Average for HCW Biologics (HCWB) over the last 6 years, with Q3 2025 value amounting to -$1.1 million.

  • HCW Biologics' Equity Average rose 8672.86% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year increase of 8672.86%. This contributed to the annual value of $3.3 million for FY2024, which is 8685.1% down from last year.
  • Per HCW Biologics' latest filing, its Equity Average stood at -$1.1 million for Q3 2025, which was up 8672.86% from -$4.3 million recorded in Q2 2025.
  • Over the past 5 years, HCW Biologics' Equity Average peaked at $52.6 million during Q4 2021, and registered a low of -$8.4 million during Q4 2024.
  • Its 5-year average for Equity Average is $20.2 million, with a median of $18.7 million in 2023.
  • Per our database at Business Quant, HCW Biologics' Equity Average skyrocketed by 39985.09% in 2021 and then crashed by 45291.33% in 2025.
  • Over the past 5 years, HCW Biologics' Equity Average (Quarter) stood at $52.6 million in 2021, then decreased by 23.97% to $40.0 million in 2022, then crashed by 53.33% to $18.7 million in 2023, then tumbled by 144.84% to -$8.4 million in 2024, then soared by 87.1% to -$1.1 million in 2025.
  • Its last three reported values are -$1.1 million in Q3 2025, -$4.3 million for Q2 2025, and -$7.7 million during Q1 2025.